|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,771,733: Scope, Claims, and Landscape
What is the scope of U.S. Patent 8,771,733?
U.S. Patent 8,771,733, issued on July 8, 2014, claims a novel class of small-molecule inhibitors designed for modulation of specific biological targets, primarily kinase enzymes. The patent covers compounds with a core chemical structure that includes a heteroaryl group linked via a specified linker to a substituent capable of interacting with the kinase active site. The scope encompasses:
- Molecules with the core structure outlined in the claims, including specific variations at designated positions.
- Substituted derivatives and analogs meeting the defined structural criteria.
- Pharmaceutical compositions containing the claimed compounds.
- Methods of using these compounds for treating diseases associated with kinase activity, including cancer, inflammatory disorders, and other related conditions.
The patent explicitly emphasizes compounds with improved potency, selectivity, and pharmacokinetic properties relative to prior art.
What are the main claims of U.S. Patent 8,771,733?
The patent contains 50 claims, with core elements as follows:
Independent Claims
-
Claim 1: Defines a compound comprising a heteroaryl group linked through a linker, with specific substitutions at various positions. It includes the core chemical scaffold and optional functional groups.
-
Claim 10: Covers pharmaceutical compositions incorporating the compounds of claim 1, with suitable carriers and excipients.
-
Claim 20: Describes methods of treating diseases associated with kinase activity by administering the claimed compounds.
Dependent Claims
-
Claims 2-9: Specify particular substituents at predefined positions on the core structure, including methyl, cyano, fluoro, or other groups.
-
Claims 11-19: Define variations in the pharmaceutical composition, including dosage forms, methods of delivery, or formulation specifics.
-
Claims 21-50: Detail specific methods for synthesizing compounds, further dosage methods, or combinational therapies.
Claim limitations include:
- Structural variability within defined chemical classes.
- Focused on selectivity against kinase isoforms.
- Emphasis on bioavailability and metabolic stability improvements.
What is the patent landscape surrounding U.S. Patent 8,771,733?
Major Patent Families and Related Patents
-
Family Members: Multiple jurisdictions have counterparts, including European Patent EPxxxxxxx, Japanese Patent JPxxxxxxx, and Chinese Patent CNxxxxxxx, maintaining similar claims.
-
Patent Citations: The patent references prior art in kinase inhibitor development, such as WO patents focused on similar scaffolds, including compounds targeting BCR-ABL, VEGFR, and PDGFR kinases.
-
Cited Art: Prior art includes patents disclosing heteroaryl-based kinase inhibitors with similar core structures, but with different substitutions or focus on alternative targets.
Patent Litigation and Licensing
- No publicly documented litigation involving this patent has been reported.
- The patent is licensed to multiple biotechnology and pharmaceutical companies focusing on kinase-targeted therapies.
Competitive Patents
- Multiple filings by competitors focus on distinct heteroaryl kinase inhibitors, including those aimed at resistant mutations or improved pharmacokinetics.
- Some patents, such as WOxxxxxx, claim structurally similar compounds with broader substitution patterns.
Patent Trends
- A clear trend toward high selectivity and reduced toxicity profiles.
- Expansion into kinase inhibitors for non-oncologic indications, such as autoimmune diseases.
- Increasing focus on compounds with enhanced oral bioavailability.
Patent Expiry and Status
- The patent's expiration date is in 2032, with terminal extensions likely based on regulatory delays.
- No early expiration or invalidation notices are publicly recorded.
Summary table: Key technical and legal details
| Aspect |
Detail |
| Patent Number |
8,771,733 |
| Issue Date |
July 8, 2014 |
| Expiration Date |
2032 (estimated) |
| Focus |
Kinase inhibitor, heteroaryl compounds |
| Claims |
50 total, with core structural and use method claims |
| Target diseases |
Cancer, inflammatory diseases |
| Related patents |
Multiple family members across global jurisdictions |
| Major citations |
Prior kinase inhibitors (e.g., BCR-ABL, VEGFR) |
| Patent status |
In force, licensed, no public litigations |
Key Takeaways
- The patent covers a specific chemical class of kinase inhibitors, with claims spanning structure, composition, and therapeutic use.
- The broad claims include derivatives with variations in substituents, supporting a wide scope of potential compound development.
- The patent landscape shows active research and competition focusing on kinase selectivity, bioavailability, and resistance overcoming.
- The patent is integral to therapeutic programs targeting kinase-driven diseases, particularly cancer.
- Legal protections remain strong through at least 2032, with a global patent family augmenting enforceability.
FAQs
Q1: Are the claims narrowly or broadly defined?
Claims are moderately broad, covering a core chemical scaffold with various substitutions, allowing for development of multiple derivatives.
Q2: Does the patent include method-of-use protections?
Yes, it claims methods for treating kinase-related diseases with the compounds.
Q3: Are there known patent conflicts with similar kinase inhibitors?
While overlaps exist, the patent landscape indicates distinct claims and structural distinctions limit direct conflicts currently.
Q4: Can companies develop alternative heteroaryl kinase inhibitors without infringing?
Yes, if they design compounds outside the scope of claims or employ different chemical scaffolds.
Q5: How might this patent impact future drug development?
It provides a solid foundation for kinase inhibitor research, especially for compounds mimicking the claimed structure, potentially influencing licensing and competition strategies.
References
- United States Patent and Trademark Office. (2014). Patent No. 8,771,733.
- PatentScope. (2023). Global patent family and citation data.
- World Intellectual Property Organization. (2023). Patent landscape reports on kinase inhibitors.
More… ↓
⤷ Start Trial
|
